Home » Authors » Trista Morrison

Articles by Trista Morrison

Elixir Raises $46M Series C For Metabolic Disease Trials

Nov. 29, 2006

By Trista Morrison

Orexigen Closes $30M Round For Late-Stage Obesity Trials

Nov. 27, 2006

By Trista Morrison

Orexigen Closes $30M Round For Late-Stage Obesity Trials

Nov. 27, 2006

By Trista Morrison

Intradigm Raises $16M For Systemic Delivery Of RNAi

Nov. 22, 2006

By Trista Morrison

Intradigm Raises $16M For Systemic Delivery Of RNAi

Nov. 22, 2006

By Trista Morrison

Neurotech Brings In $35M For Phase II Retinal Disease Trials

Nov. 17, 2006

By Trista Morrison

Neurotech Brings In $35M For Phase II Retinal Disease Trials

Nov. 17, 2006

By Trista Morrison

Biotech's Business Models Evolve As Industry Matures

Nov. 16, 2006

By Trista Morrison

Biotech's Business Models Evolve As Industry Matures

Nov. 16, 2006

By Trista Morrison

Sofinnova Closes $375M Fund To Support Spinouts

Nov. 15, 2006

By Trista Morrison

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...